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"The alcoholism can also deal with drug treatments." 
This is the message that emerges from the press conference of presentation of Campral, trade name of 
acamprosate, a neuromodulator specifically indicated in the maintenance of abstinence in alcohol-
dependent patients.Alcoholism is a disease characterized by: craving, loss of control, tolerance and 
physical dependence.For many years the prevention of relapse in use of alcohol after detoxification was 
supported almost exclusively by psychosocial procedures and techniques with modest success. Treatment 
with acamprosate is a valid tool to complement psychotherapy as it does not cause addiction, abuse or 
withdrawal of its suspension and does not interfere with other medications that patients often alcoholics 
must take.To evaluate the effectiveness, our study evaluated the effects of Acamprosate compared to 
GHB in clinical-physiological and social health in a way indicators of a possible therapeutic success in 
terms of abstinence from alcohol and social reintegration. The hypothesis of the project is that 
pharmacotherapy anticraving with acamprosate integrated with psycho-social support, can reduce relapse 
in alcohol together with the reduction of the risk of abuse arising from the use of GHB. This work 
purports to be an account of 11 months of observation of patients treated with acamprosate. 
Results: A total of 36 patients were observed, of which 5, 4 men and 1 woman at the Ser.T Alcamo and 
31, 21 men and 10 women at the Ser.T of Palermo. In the fight against alcoholism, this therapy with 
acamprosate offers significant potential: decreases, in fact, the incidence, severity and frequency of 
relapses (Fig. 1). As regards the craving, during the period of treatment with acamprosate, there has been 
a change, in the sense of reduction, of craving for alcohol: if before therapy was in 68% of cases, 
medium-high, becomes after 3-4 months after therapy in low-nil in 89% of patients observed. 
It has been recorded that, after 3-4 months after receiving acamprosate, the clinical picture of the patient 
is greatly improved by referring to biological markers (Fig. 2).  
Conclusions: The study shows that treatment with acamprosate is an exciting opportunity within a project 
of integrated care for the treatment of alcohol addiction. The acamprosate may also be used early in the 
pharmacological treatment of dependence on alcohol to prevent the appearance of excitability neuronal 
associated abstinence.On the other hand, its use must have a duration sufficient to allow neuronal 
excitability to normalize in the most enduring possible: the treatment, in fact, is recommended for one 
year. In any case, the use can be continued even in the face of relapses, with the aim to reduce the 
frequency or severity.In particular, the strong point seems to be the ability for the user to experience a 









Fig.1: Percentage of relapse during 









Fig.2: Laboratory findings on biological markers before and after treatment with acamprosate. 
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